Curis
CRIS
$14.52
Share price
-1.69%
Change (1 day)
1,761.54%
Change (1 year)
Categories
P/S ratio for Curis (CRIS)
P/S ratio as of April 2024 (TTM): 8.69
According to Curis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.68559. At the end of 2023 the company had a P/S ratio of 7.50.
P/S ratio history for Curis from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 7.50 | 43.71% |
| 2022 | 5.22 | -87.26% |
| 2021 | 40.9 | -38.66% |
| 2020 | 66.8 | 1081.79% |
| 2019 | 5.65 | 157.53% |
| 2018 | 2.19 | -81.09% |
| 2017 | 11.6 | -79.84% |
| 2016 | 57.5 | 20.72% |
| 2015 | 47.6 | 263.4% |
| 2014 | 13.1 | -18.77% |
| 2013 | 16.1 | -0.2% |
| 2012 | 16.2 | -33.39% |
| 2011 | 24.3 | 155.42% |
| 2010 | 9.50 | -62.68% |
| 2009 | 25.5 | 347.65% |
| 2008 | 5.69 | 50.44% |
| 2007 | 3.78 | -9.14% |
| 2006 | 4.16 | -73.01% |
| 2005 | 15.4 | -69.21% |
| 2004 | 50.1 | 203.15% |
| 2003 | 16.5 | 829.16% |
| 2002 | 1.78 | -98.93% |
| 2001 | 167 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 2.54 | -70.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 2.20 | -74.67% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 8.22 | -5.40% | 🇺🇸 USA |
 Exelixis EXEL | 3.79 | -56.36% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | 353 | 3,968.32% | 🇺🇸 USA |
 Cel-Sci
CVM | N/A | N/A | 🇺🇸 USA |
 Emergent BioSolutions
EBS | 0.0998 | -98.85% | 🇺🇸 USA |